Mnemonics for sPESI and PESI Scores
Simplified PESI (sPESI) Mnemonic: "CHAMPS"
The sPESI score uses 6 binary variables (1 point each), and you can remember them with "CHAMPS": 1
- Cancer (active, diagnosed within 12 months or undergoing treatment) 1
- Heart rate ≥110 bpm 1
- Age >80 years 1
- Malfunction of cardiopulmonary system (chronic cardiopulmonary disease) 1
- Pressure <100 mmHg systolic 1
- Saturation <90% (arterial oxygen saturation, with or without supplemental oxygen) 1
A score of 0 = low risk (30-day mortality 1.0-1.1%); ≥1 = high risk 1, 2
Original PESI Mnemonic: "CHAMP SMART"
The original PESI is more complex with 11 weighted variables. Remember "CHAMP SMART": 1
- Cancer (+30 points) 1
- Heart failure (+10 points) 1
- Age (actual age in years) 1
- Male sex (+10 points) 1
- Pulse ≥110 bpm (+20 points) 1
Systolic BP <100 mmHg (+30 points) 1
- Mental status altered (+60 points) 1
- Arterial oxygen saturation <90% (+20 points) 1
- Respiratory rate >30 breaths/min (+20 points) 1
- Temperature <36°C (+20 points) 1
Plus chronic pulmonary disease (+10 points) 1
Risk Classes: Class I (≤65 points, 1.6% mortality), Class II (66-85 points, 3.5% mortality), Class III (86-105 points, 7.1% mortality), Class IV (106-125 points, 11.4% mortality), Class V (≥126 points, 23.9% mortality) 1
Clinical Application Pearls
The sPESI is preferred in clinical practice due to its simplicity while maintaining equivalent prognostic accuracy to the original PESI (both with area under the curve ~0.75-0.84). 1, 2
- Low-risk patients (PESI Class I/II or sPESI=0) are candidates for outpatient management with direct oral anticoagulants when exclusion criteria are absent 3, 4
- The sPESI classifies 30-36% of patients as low risk compared to 36-49% with original PESI, with both showing excellent negative predictive value for 30-day mortality 1, 2
- In cancer patients, these scores require additional validation, as the original derivation studies included limited numbers of oncology patients 1, 5
- The presence of right ventricular dysfunction on imaging or elevated cardiac biomarkers should prompt further risk stratification even in low PESI/sPESI patients, as these findings may warrant inpatient observation 1, 4